How are humanised antibodies produced?
Human chimeric monoclonal antibodies are produced in transgenic mouse strains in which the sequence for mouse IgG1 fc region is substituted with the human sequence. After mouse immunisation and the use of hybridoma technology, antibodies are generated that retain a human constant region for recognition by the anti-human conjugate.
Autoantibodies against intracellular antigens are commonly found in connective tissue disorders. One example is SLE which can involve joints, kidneys, skin, mucous membranes and blood vessel walls. The idiopathic inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are characterised by the presence of inflammatory infiltrates within the skeletal muscle.
Autoantibodies to tRNA synthetases are closely linked with AM/PM detection and diagnosis. Autoantibodies against PL-7 and PL-12 have been found in up to 6% of myositis patients. Anti SRP autoantibodies are mainly associated with a syndrome of a necrotising myopathy and severe prognosis. Autoantibodies against MI-2 are considered specific serological markers of DM. Detected in about 20% of myositis sera they are proven markers for acute onset and good response to therapy. Autoantibodies against PCNA are detected in about 5-10% of SLE patients.
Are you developing an In Vitro assay?
BBI now offers these specificities for IVD manufacturers developing in vitro assays that require a consistent, reliable source of raw material positive calibrator and quality control materials. Materials are stored and shipped from our Freiburg facilities. From this facility our materials are prepared and supplied directly to clients in Europe and non-China Asian territories. For customers in America and China, our Freiburg products are distributed through our carefully selected and highly reputable partners.
The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.
Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.
Novarum™ technology transforms a smartphone into a diagnostic test reader, empowering users to read and share the results of rapid tests from the point of care. Our pioneering technology can be used by anyone, anywhere, with minimal training: connecting patients and doctors, field workers, lab researchers and primary care clinicians to specialist practices as part of a mobile eco-system.